Lineage Cell Therapeutics (XTAE:LCTX) Other Long Term Assets : ₪2.20 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Other Long Term Assets?

Lineage Cell Therapeutics's other long-term assets for the quarter that ended in Mar. 2024 was ₪2.20 Mil.

Lineage Cell Therapeutics's quarterly other long-term assets increased from Sep. 2023 (₪2.04 Mil) to Dec. 2023 (₪2.13 Mil) and increased from Dec. 2023 (₪2.13 Mil) to Mar. 2024 (₪2.20 Mil).

Lineage Cell Therapeutics's annual other long-term assets declined from Dec. 2021 (₪2.33 Mil) to Dec. 2022 (₪2.31 Mil) and declined from Dec. 2022 (₪2.31 Mil) to Dec. 2023 (₪2.13 Mil).

Lineage Cell Therapeutics Other Long Term Assets Historical Data

The historical data trend for Lineage Cell Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Other Long Term Assets Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

3.19

2.27

2.33

2.31

2.13

Lineage Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial															2.34	2.17	2.04	2.13	2.20

Lineage Cell Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

LCTX:USA BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.